Phase 1 Myeloma Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who have given written consent to participate voluntarily, before any study-related procedures begin.
• People who have a confirmed diagnosis of multiple myeloma with measurable disease shown through specific blood, urine, or bone marrow tests (confirm with trial site for exact measurements).
• People who have previously been treated with a medication called Carfilzomib.
• People who are 18 years of age or older at the time of signing the consent form.
• People who are reasonably active and able to care for themselves, with only mild limitations on physical activity (an ECOG score of less than 2 — confirm with trial site if unsure what this means).
• People who have completed an initial course of treatment ("induction therapy") but have not achieved a complete response to that treatment.
• People who have a life expectancy of more than 12 weeks.
• People whose blood test results meet specific levels for white blood cells, platelets, haemoglobin, and liver function (the trial site will check these).
• People who have had a heart scan (MUGA or echocardiogram) within the past 6 months showing the heart is pumping adequately.
• Women who could become pregnant must have a negative pregnancy test within 7 days before starting treatment, and again within 24 hours before the first dose.
• Women who could become pregnant, and men who are sexually active with women who could become pregnant, must agree to use two highly effective forms of contraception during the study and for 90 days after the last dose.
• Male participants must agree not to donate sperm while taking Carfilzomib and for 90 days after the last dose.

Who may not be able to join:

• People who have had allergic reactions to Carfilzomib or to compounds containing an ingredient called captisol.
• People with serious heart conditions, including severe heart failure (NYHA Class III or IV), unstable angina, severe uncontrolled irregular heartbeat, signs of acute heart strain on an ECG, significant conduction problems, or a heart attack within the past 6 months.
• People with uncontrolled high blood pressure.
• People with high blood pressure in the lungs (pulmonary hypertension).
• People with a known HIV infection, active hepatitis C, or active hepatitis B (though people with hepatitis B or C who have achieved a sustained response after antiviral treatment may still be considered — confirm with trial site).
• People with an active viral or bacterial infection, or another existing medical condition that would significantly increase the risks of this treatment.
• People with any uncontrolled medical condition, abnormal lab results, or psychiatric illness that could place them at unacceptable risk, including uncontrolled diabetes, active uncontrolled infection, or active chronic liver disease such as hepatitis or cirrhosis.
• People with moderate or severe nerve damage in the hands or feet (Grade 2 or higher peripheral neuropathy).
• People who have been diagnosed with or treated for another cancer within the past 3 years, with some exceptions such as certain fully removed skin cancers, in-situ cancers, or low-risk prostate cancer that has been treated (confirm with trial site).
• People who have received radiation therapy within 3 weeks before enrolling in the trial.
• People who have previously had stem cell mobilisation or a stem cell transplant.

Important: Always verify eligibility with the trial site directly before applying.